Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Received Approval of XEGLYZE™ (abametapir) Lotion, 0.74%, in the U.S.
Details : XEGLYZE (Abametapir), contains benzyl alcohol. Systemic exposure to benzyl alcohol has been associated with serious and fatal adverse reactions including “gasping syndrome” in neonates and low birth weight infants.
Product Name : Xeglyze
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2014
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Accelovance | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2014
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Accelovance | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2014
Lead Product(s) : Abametapir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : TKL Research, Inc. | Accelovance
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2014
Lead Product(s) : Abametapir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : TKL Research, Inc. | Accelovance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Accelovance | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2014
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Accelovance | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2013
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2012
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2011
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
